Cheng Quah

About

Cheng brings over a decade of drug development experience to Kinnate. She joins us from Arcus Biosciences where she was the product development team lead for the GI oncology program, overseeing the early phase clinical trials and establishing the clinical development strategy for portfolio molecules across the GI program. She has led clinical teams in global filings for Calquence (acalabruitinib)* in chronic lymphocytic leukemia (CLL), and Avastin (bevacizumab)* in breast and ovarian cancer and managed Phase III and Phase II studies in melanoma in her previous roles at Acerta (Astra-Zeneca) and Genentech-Roche. She began her career as a faculty member in anesthesiology at the University of California, San Francisco after completing a residency at Massachusetts General Hospital (Harvard University). She holds an MBBS(Hon) from the University of Sydney, Australia.